title: Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma.
abstract: BACKGROUND
  Recently, maintaining higher relative dose intensity (RDI) of chemotherapeutic drugs has become a widespread practice in an attempt to achieve better outcomes in the treatment of aggressive lymphoma. The addition of rituximab to chemotherapy regimens has significantly improved outcome in diffuse large B-cell lymphoma (DLBL). However, it is unknown if higher RDI in chemotherapy when combined with rituximab leads to a better outcome in aggressive B-cell lymphoma.
  
  
  METHODS
  We retrospectively evaluated the impact of the RDI of initial chemotherapy (consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone with rituximab (R-CHOP) on outcome in 100 newly diagnosed DLBL patients.
  
  
  RESULTS
  A multivariate Cox regression model showed that RDI trended towards a significant association with mortality [hazard ratio per 0.1 of RDI = 0.8; 95% confidence interval 0.6-1.0; P = 0.08]. Additionally, on multivariate logistic analysis, advanced age was a significant factor for reduced RDI.
  
  
  CONCLUSIONS
  Our data suggest that in DLBL patients, mortality was affected by RDI of R-CHOP as the initial treatment, and the retention of a high RDI could therefore be crucial.
authors.affiliation: Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan. teraday@med.osaka-cu.ac.jp
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Terada
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Ran
authors.initials: R
authors.lastname: Aimoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kanashima
authors.forename: Erina
authors.initials: E
authors.lastname: Sakamoto
authors.forename: Mizuki
authors.initials: M
authors.lastname: Aimoto
authors.forename: Eri
authors.initials: E
authors.lastname: Inoue
authors.forename: Hideo
authors.initials: H
authors.lastname: Koh
authors.forename: Takahiko
authors.initials: T
authors.lastname: Nakane
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Takeoka
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ohsawa
authors.forename: Ki-Ryang
authors.initials: KR
authors.lastname: Koh
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yamane
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Nakao
authors.forename: Kensuke
authors.initials: K
authors.lastname: Ohta
authors.forename: Atsuko
authors.initials: A
authors.lastname: Mugitani
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Teshima
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D009367:Neoplasm Staging; D011239:Prednisolone; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone
references.citation: Blood. 1994 Sep 1;84(5):1361-92
references.pmid: 8068936
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3187-205
references.pmid: 16682719
references.citation: Cancer. 2003 Dec 15;98(12):2651-6
references.pmid: 14669285
references.citation: Oncogene. 2004 Apr 29;23(20):3530-40
references.pmid: 15077178
references.citation: Lancet Oncol. 2006 May;7(5):379-91
references.pmid: 16648042
references.citation: Ann Hematol. 2008 Apr;87(4):277-83
references.pmid: 17952688
references.citation: Cancer Res. 2001 Jul 1;61(13):5137-44
references.pmid: 11431352
references.citation: Lancet Oncol. 2008 Feb;9(2):105-16
references.pmid: 18226581
references.citation: Cancer Biother Radiopharm. 1997 Jun;12(3):177-86
references.pmid: 10851464
references.citation: Cancer. 1976 Oct;38(4):1484-93
references.pmid: 791473
references.citation: Br J Haematol. 2009 Mar;144(5):677-85
references.pmid: 19055662
references.citation: Isr J Med Sci. 1988 Sep-Oct;24(9-10):533-8
references.pmid: 3060443
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Cancer. 1990 Sep 15;66(6):1124-9
references.pmid: 2205353
references.citation: J Clin Oncol. 2004 Nov 1;22(21):4302-11
references.pmid: 15381684
references.citation: Ann Oncol. 1993 Sep;4(8):651-6
references.pmid: 7694634
references.citation: N Engl J Med. 1993 Apr 8;328(14):1002-6
references.pmid: 7680764
references.citation: J Clin Oncol. 1990 Jun;8(6):963-77
references.pmid: 2348230
references.citation: N Engl J Med. 1993 Sep 30;329(14):987-94
references.pmid: 8141877
references.citation: Eur J Cancer. 2006 Oct;42(15):2433-53
references.pmid: 16750358